Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure
- Authors
- Kim, Hyun-Jin; Jo, Sang-Ho; Lee, Min-Ho; Seo, Won-Woo; Choi, Jin-Oh; Ryu, Kyu-Hyung
- Issue Date
- Sep-2020
- Publisher
- SPRINGER
- Keywords
- Angiotensin-converting enzyme inhibitor; Angiotensin receptor blockers; Beta-blocker; Ejection fraction; Heart failure
- Citation
- ADVANCES IN THERAPY, v.37, no.9, pp.3839 - 3849
- Indexed
- SCIE
SCOPUS
- Journal Title
- ADVANCES IN THERAPY
- Volume
- 37
- Number
- 9
- Start Page
- 3839
- End Page
- 3849
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/8927
- DOI
- 10.1007/s12325-020-01443-6
- ISSN
- 0741-238X
- Abstract
- Introduction
Use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) only, beta-blockers (BB) only, or both has been rarely compared in patients with heart failure (HF). We evaluated the prescribing patterns of ACEi/ARB and BB on prognosis in HF according to left ventricular function.
Methods
Study data were obtained from a national multicenter cohort that included patients hospitalized for HF. Patients were classified into four groups according to the prescription pattern at discharge: all ACEi/ARB and BB treatment group, only ACEi or ARB treatment group, only BB treatment group, and neither ACEi/ARB nor BB group.
Results
Use of both ACEi/ARB and BB had significantly lowest all-cause death rates among the four groups in all types of HF. Cox regression analysis showed that use of both drugs was independently associated with 51% reduced risk of all-cause death in patients with HF with preserved ejection fraction (HFpEF) and HF with mid-range ejection fraction (HFmrEF). Treatment with only ACEi/ARB also showed an independent association with a 52% reduction in this group. However, only BB treatment was not associated with reducing long-term mortality in patients with HFpEF and HFmrEF. In patients with HF with reduced ejection fraction, use of ACEi/ARB and/or BB revealed an independent association with a reduced risk of all-cause death regardless of prescribing patterns.
Conclusions
Prescribing patterns were diverse in HF and there was a difference in the degree of risk reduction in all-cause death. In particular, clinicians should consider ACEi/ARB first for patients with HFpEF and HFmrEF prior to BB.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.